In a meta-analysis of seven trials in type 2 diabetes, shorter diabetes duration was associated with a significantly greater but clinically non-relevant HbA1c reduction on liraglutide 1.2 mg (0.18% per 10 years shorter).
In plain wordsIn adults with type 2 diabetes, a shorter diabetes history was linked to a slightly bigger HbA1c drop on liraglutide 1.2 mg.
- Peptide
- Liraglutide
- Outcome
- Not applicableHbA1c reduction by diabetes duration, liraglutide 1.2 mg
- Study
n = 3,222
- Comparator
- Placebo
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 1.2 mg · up to 28 weeksAs given in this study (human).
Measurements
- HbA1c reduction per 10 years shorter duration
- 0.18%
- liraglutide 1.2 mg
Source sentences
With liraglutide 1.2 mg, shorter diabetes duration was associated with a significantly greater, but clinically non-relevant, difference in glycated haemoglobin (HbA1c) reduction (p < 0.05), i.e. a 0.18% (1.96 mmol/mol) reduction in HbA1c per 10 years shorter diabetes duration.
2 context sentences(design, population, supporting numbers)
This meta-analysis of seven randomized, placebo-controlled studies (total 3222 patients) evaluated whether type 2 diabetes (T2D) duration affects the changes in blood glucose control and body weight that can be achieved with liraglutide and placebo.
Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials.